LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Interest in Commercial Applications for Proteomics Continues to Grow

By LabMedica International staff writers
Posted on 15 Oct 2014
Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies.

Proteomics is the study of the structure and function of proteins. This includes the study of which proteins are expressed, when and where they are expressed, and of interactions with proteins and other types of molecules. Many drug targets are proteins, and proteomics is an important tool for identification and characterization of novel drug targets. Furthermore, proteomics is an important tool for the identification of novel biomarkers and biomarker panels for diagnosis of diseases.

Among the significant business connections cited in the recent report “Proteomics Markets for Research and IVD Applications” published by Kalorama Information (New York, NY, USA) were:

Thermo Fisher Scientific (Milford, MA, USA) and Nuclea Biotechnologies (Pittsfield, MA, USA) will develop multiplexed mass spectrometry-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations.

BG Medicine (Waltham, MA, USA) and Kindstar Diagnostics (China) announced an agreement under which Kindstar will offer galectin-3 testing services in China.

Biocartis (Mechelen, Belgium) and Invetech (Melbourne (Australia) announced a collaboration agreement to support development and manufacture of Evalution, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers. Invetech provides instrument development, custom automation, and contract manufacturing.

“There is a lot of interest in identification and validation of novel biomarkers that may represent potential drug targets or may lead to novel diagnostic tests,” said Bruce Carlson, publisher of Kalorama Information. “Researchers are looking to proteomics for these discoveries.”

Related Links:

Kalorama Information


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more